Holen Sie sich die Stockscreener-App
7.5351
3.40%
-0.2649
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Will BioCryst Pharmaceuticals Inc. stock beat EPS estimatesRisk Management Strategies & Invest Smarter With Signals - bollywoodhelpline.com
Astria faces shareholder lawsuits over planned BioCryst merger - MSN
Charlie Gayer to be BioCryst CEO effective January 1 - The Pharma Letter
BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says - marketscreener.com
Rice Hall James & Associates LLC Sells 179,891 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily
Trade Report: Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zone2025 Market Sentiment & Advanced Technical Signal Analysis - moha.gov.vn
Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks
Alane Barnes Sells 21,773 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets
1-year trial data: Orladeyo cuts swelling attacks in young children - Angioedema News
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 - Insider Monkey
Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reports2025 Volume Leaders & AI Optimized Trade Strategies - Улправда
Is BioCryst Pharmaceuticals Inc. stock supported by strong fundamentalsBond Market & Short-Term High Return Strategies - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve
Published on: 2025-12-19 20:19:26 - ulpravda.ru
Will BioCryst Pharmaceuticals Inc. stock deliver strong dividend growthGold Moves & Free Community Supported Trade Ideas - DonanımHaber
How BioCryst Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Selloffs & Expert Curated Trade Setup Alerts - DonanımHaber
What is the fair value of BioCryst Pharmaceuticals Inc. stock now2025 Support & Resistance & Safe Capital Growth Stock Tips - DonanımHaber
ETF Watch: What is the fair value of BioCryst Pharmaceuticals Inc. stock now2025 Support & Resistance & Safe Capital Growth Stock Tips - DonanımHaber
EDGAR Filing Documents for 0001140361-25-046040 - SEC.gov
Astria Therapeutics (NASDAQ: ATXS) details terms of BioCryst merger and special vote - Stock Titan
BioCryst Pharmaceuticals (BCRX) details cash and stock deal to acquire Astria - Stock Titan
Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zone2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
Published on: 2025-12-18 17:50:37 - ulpravda.ru
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (BCRX) officer reports 8,181-share tax withholding - Stock Titan
Q4 Earnings Estimate for BCRX Issued By HC Wainwright - MarketBeat
BioCryst Pharmaceuticals (BCRX) CLO reports tax withholding and share sale - Stock Titan
CEO Stonehouse Surrenders 27,368 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView — Track All Markets
BioCryst Pharmaceuticals (NASDAQ: BCRX) CEO reports tax share withholding - Stock Titan
BioCryst Pharma stock price target raised to $32 by H.C. Wainwright - Investing.com Canada
HC Wainwright Has Bullish Estimate for BCRX FY2025 Earnings - MarketBeat
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? - Yahoo Finance
FDA extends Orladeyo approval to children as young as 2 - Angioedema News
BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
Officer Barnes Files To Sell 21,210 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView — Track All Markets
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval By Investing.com - Investing.com Nigeria
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval - Investing.com Nigeria
BioCryst releases preliminary 2024 results, 2025 guidance - MSN
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - sharewise.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
The Technical Signals Behind (BCRX) That Institutions Follow - news.stocktradersdaily.com
Aug Highlights: Is BioCryst Pharmaceuticals Inc stock oversold or undervaluedJuly 2025 Sentiment & Risk Controlled Swing Alerts - moha.gov.vn
FDA approves BioCryst’s oral pellet version of rare disease drug for children - WKZO
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst wins FDA approval for Orladeyo oral pellets - MSN
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharma stock maintains Buy rating at TD Cowen on Orladeyo pediatric approval - Investing.com
2.71%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):